Editorial: Formulation and Delivery of Biologics

This is a preview of subscription content, log in to check access.

References

  1. 1.

    ResearchAndMarkets.com. Global Biologics Market Report (2020 to 2030) - COVID-19 Impact and Recovery Available from: https://www.businesswire.com/news/home/20200522005337/en/Global-Biologics-Market-Report-2020-to-2030%2D%2D-COVID-19-Impact-and-Recovery%2D%2D-ResearchAndMarkets.com.

  2. 2.

    Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(9):1126–36.

    CAS  Article  Google Scholar 

  3. 3.

    Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Simeon R, Chen Z. In vitro-engineered non-antibody protein therapeutics. Protein Cell. 2018;9(1):3–14.

    CAS  Article  Google Scholar 

  5. 5.

    Gupta S, Alaarg A, Wu Z, Lu X, Garripelli V, Dong H, et al. Chapter 18: Design of Clinical in-use Studies. In: Jameel F, Skoug JW, Nesbitt RR, editors. Development of biopharmaceutical drug-device products. Cham: Springer International Publishing; 2020. p. 431–59.

  6. 6.

    Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14(3):559–70.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Kumar S, Plotnikov NV, Rouse JC, Singh SK. Biopharmaceutical informatics: supporting biologic drug development via molecular modelling and informatics. J Pharm Pharmacol. 2018;70(5):595–608.

    CAS  Article  Google Scholar 

  8. 8.

    Halley J, Chou YR, Cicchino C, Huang M, Sharma V, Tan NC, et al. An industry perspective on forced degradation studies of biopharmaceuticals: survey outcome and recommendations. J Pharm Sci. 2020;109(1):6–21.

  9. 9.

    Weiss WF, Young TM, Roberts CJ. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci. 2009;98(4):1246–77.

    CAS  Article  Google Scholar 

  10. 10.

    Domnowski M, Jaehrling J, Frieß W. Assessment of antibody self-interaction by bio-layer-interferometry as a tool for early stage formulation development. Pharm Res. 2020;37(2):29.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Melien R, Garidel P, Hinderberger D, Blech M. Thermodynamic unfolding and aggregation fingerprints of monoclonal antibodies using thermal profiling. Pharm Res. 2020;37(4):78.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Rao VA, Kim JJ, Patel DS, Rains K, Estoll CR. A comprehensive scientific survey of excipients used in currently marketed. Therapeutic Biological Drug Products Pharmaceutical Research. 2020;37(10):200.

    CAS  PubMed  Google Scholar 

  13. 13.

    ICH. Guidance for Industry - Q8(R2) Pharmaceutical development. In.; 2019.

  14. 14.

    Sreedhara A, Yin J, Joyce M, Lau K, Wecksler AT, Deperalta G, et al. Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development. Eur J Pharm Biopharm. 2016;100:38–46.

  15. 15.

    Schöneich C. Photo-degradation of therapeutic proteins: mechanistic aspects. Pharm Res. 2020;37(3):45.

    Article  PubMed  Google Scholar 

  16. 16.

    Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505–23.

    CAS  Article  Google Scholar 

  17. 17.

    Bluemel O, Buecheler JW, Rodrigues MA, Geraldes V, Hoelzl G, Bechtold-Peters K, et al. Cryoconcentration and 3D temperature profiles during freezing of mAb solutions in large-scale PET bottles and a novel scale-down device. Pharm Res. 2020;37(9):179.

  18. 18.

    Krämer I, Thiesen J, Astier A. Formulation and Administration of Biological Medicinal Products. Pharm Res. 2020;37(8):159.

    Article  Google Scholar 

  19. 19.

    Besheer A, Mahler HC, Matter-Schwald A, Barrenechea SM, Vogt M, Chalus P, et al. Evaluation of different quality-relevant aspects of closed system transfer devices (CSTDs). Pharm Res. 2020;37(4):81.

  20. 20.

    Mantha N, Burra S, Rajagopal K, Sreedhara A. Protein stability and Photostability under in vitro Vitreal conditions – implications for long acting delivery of protein therapeutics for ocular disease. Pharm Res. 2020;37(5):85.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Ahmed Besheer or Hanns-Christian Mahler.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Guest Editors: Ahmed Besheer and Hanns-Christian Mahler

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Besheer, A., Mahler, HC. Editorial: Formulation and Delivery of Biologics. Pharm Res 37, 225 (2020). https://doi.org/10.1007/s11095-020-02956-z

Download citation

KEY WORDS

  • administration
  • biologics
  • compatibility
  • excipients
  • formulation
  • parenteral drug product